We’re excited to announce that Biocytogen will attend the American Diabetes Association (ADA) 2025 Scientific Sessions as an exhibitor! Visit us at Booth #2139 to connect with our team, explore our biopharma diabetes research, and discover how our mouse models, antibody discovery platforms, and integrated preclinical solutions are accelerating breakthroughs in metabolic disease research. We look forward to meaningful conversations and potential collaborations—see you there!
What is American Diabetes Association?
The American Diabetes Association (ADA) Scientific Sessions is the world’s largest diabetes-focused conference, bringing together over 9,000 global professionals in diabetes research, treatment, and care. This year, it is held at McCormick Place in Chicago; this premier event offers exhibitors the chance to connect with physicians, clinicians, scientists, and healthcare leaders to showcase innovative products, services, and solutions that advance diabetes management and improve patient outcomes.
Event Overview
Date: June 20, 2025 - June 23, 2025
Venue: McCormick Place Convention Center, 2301 S Martin Luther King Dr, Chicago, IL
Event Schedule
The meeting dates for ADA 2025 are June 20, 2025, to June 23, 2025. The event will include exhibitor shows and industry learning opportunities. For more information, please visit ADA 2025.
About BIOCYTOGEN
Biocytogen is a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies. Founded on gene editing technology, Biocytogen leverages genetically engineered proprietary RenMice® platforms for fully human monoclonal antibody discovery, and has established a sub-brand, RenBiologics™, to explore global partnerships for an off-the-shelf library of >400,000 fully human antibody sequences against approximately 1000 targets for worldwide collaboration. Biocytogen pioneered the generation of drug target knock-in humanized models for preclinical research, and currently provides a few thousand off-the-shelf animal and cell models under the company's sub-brand, BioMice™, along with preclinical pharmacology and gene-editing services for clients worldwide. Headquartered in Beijing, Biocytogen has branches in China (Haimen Jiangsu, Shanghai), USA(Boston, San Francisco), and Germany (Heidelberg).
We look forward to meeting you at the ADA 2025 Scientific Sessions in Chicago, IL!
